Dave Abramowitz is currently the unified product management and product ownership team for chromatography and mass spectrometry software at Thermo Fisher Scientific, and previously served as the ecosystem product portfolio leader for the analytical instrumentation group. Dave has more than 15 years of experience in digital solutions and platform implementation in life sciences markets.
Dave Abroamowitz of Thermo Fisher Scientific concludes his five-part video series with thoughts on how laboratories can address potential biases or errors introduced by artificial intelligence (AI) models, especially when these analyses inform high-stakes decisions such as clinical research or regulatory submissions.
Artificial intelligence (AI) will of course revolutionize method development, peak detection, and data interpretation as it becomes more widely applied and accepted. We asked Dave Abramowitz of Thermo Fisher Scientific if there might be other areas of chromatography that may be equally transformed in the next decade.
High-quality, well-labeled data is essential. What steps are being taken—or should be taken—to create standardized, shared chromatographic datasets for AI training? Dave Abramowitz of Thermo Fisher Scientific shares his insights.
What role will human expertise have when artificial intelligence (AI) becomes more deeply embedded in chromatography workflows? Dave Abramowitz of Thermo Fisher Scientific shares his thoughts.
Dave Abramowitz of Thermo Fisher Scientific on how he sees artificial intelligence (AI)-driven chromatography tools scaling from research labs to regulated pharmaceutical environments, where compliance and validation are critical, in this first part of our video interview series.
